Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2024-01-09 00:00:00 ET · period of report 2024-01-06 · accession 0001209191-24-001268 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-09 | 2024-01-08 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $29.96 | -731 | 30.9K | -2% | -$21.9K |
| D | 2024-01-09 | 2024-01-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | — | +1,287 | 31.7K | +4% | — |
| D | 2024-01-09 | 2024-01-06 | ACAD | Teehan Brendan | EVP, COO, Head of Commercial | M - OptEx | $0.00 | -1,287 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-08 | S | D | 731 | $29.96 | 30,949 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.61 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 2 | Common | Common Stock | 2024-01-06 | M | A | 1,287 | — | 31,680 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| 3 | Derivative | Restricted Stock Units | 2024-01-06 | M | D | 1,287 | $0.00 | 0 | D | — · — to — | 1,287 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F4) One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. |